Stockscreener 앱 받기
56.60
3.44%
1.88
시간 외 거래:
56.61
0.010
+0.02%
전일 마감가:
$54.72
열려 있는:
$55.745
하루 거래량:
12.65M
Relative Volume:
1.10
시가총액:
$115.58B
수익:
$48.48B
순이익/손실:
$7.27B
주가수익비율:
15.89
EPS:
3.5626
순현금흐름:
$11.91B
1주 성능:
-0.54%
1개월 성능:
-1.36%
6개월 성능:
+8.95%
1년 성능:
+18.04%
1일 변동 폭
$55.55
$56.78
1주일 범위
$54.20
$57.45
52주 변동 폭
$42.52
$62.89
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
56.60 | 111.74B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,125.27 | 961.99B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.17 | 537.39B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.94 | 383.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.26 | 283.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
148.40 | 274.12B | 54.66B | 13.58B | 16.05B | 7.0171 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb Co (BMY) Shares Surge 3.4% -- What GF Score of 78 Tells Investors - GuruFocus
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Bristol Myers Squibb vs Pfizer Dividend Stock Comparison 2026News and Statistics - IndexBox
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? - The Motley Fool
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Bristol-Myers Squibb stock (US1078421011): modest move as oncology data and institutional flows draw - AD HOC NEWS
Westpac Banking Corp Purchases 46,386 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate - PMLiVE
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? - The Motley Fool
Bank of New York Mellon Corp Has $1.32 Billion Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company stock (US0897961004): options activity spikes as new cancer trial data - AD HOC NEWS
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - MarketBeat
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks - AOL.com
Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors - TipRanks
BMS-Hengrui deal strikes panic in Washington - BioWorld News
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors (NYSE:BMY) - Seeking Alpha
BMY: Positive Interim Results for Bristol Myers' Iza-bren in Can - GuruFocus
Bristol-Myers Squibb CoIzalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC - TradingView
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Track Mixed Returns And Earnings Outlook - Yahoo Finance
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice - Fierce Biotech
UBS raises Bristol-Myers Squibb stock price target on pipeline outlook - Investing.com
Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines - BioSpace
Bristol-Myers Squibb’s Stock Looks Cheap on the Surface, but Hidden Risks Lurk Beneath - NAI500
Bristol Myers' Growth Portfolio Just Overtook The Legacy One - Seeking Alpha
Bristol-Myers Squibb Co (BMY) Shares Fall 3.9% -- What GF Score of 77 Tells Investors - GuruFocus
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol Myers Squibb slips as investors weigh long-term pricing and patent-cliff risks despite FDA review news - Quiver Quantitative
Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): focus on Bristol Myers deal and China A-share - AD HOC NEWS
Bristol Myers Squibb CEO on cancer developments in the pipeline - CNBC
Cullen Enhanced Equity Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Full Transcript: Bristol-Myers Squibb Q1 2026 Earnings Call - Benzinga
BioNTech (BNTX) and BMS show high NSCLC response rates with pumitamig - Stock Titan
BMY: FDA Reviews Camzyos for Adolescent Hypertrophic Cardiomyopa - GuruFocus
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1 - Yahoo Finance
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma - BioSpace
FDA accepts Bristol Myers Squibb adolescent oHCM application By Investing.com - Investing.com Canada
FDA accepts Bristol Myers Squibb adolescent oHCM application - Investing.com
Sfmg LLC Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
US big pharma vents over Australia’s drug pricing and approvals - AFR
Peapack Gladstone Financial Corp Has $24.27 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Nomura Asset Management Co. Ltd. Decreases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
MUFG Securities EMEA plc Raises Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
BioNTech SE stock (US09075V1026): ASCO lung cancer data with Bristol Myers Squibb puts oncology pipe - AD HOC NEWS
Bristol-Myers Squibb (BMY) Stock Analysis: Navigating a 10.32% Potential Upside Amidst Healthcare Innovation - DirectorsTalk Interviews
Encouraging efficacy data for BioNTech and BMS’s pumitamig shown at ASCO - The Pharma Letter
Black Swift Group LLC Purchases New Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMY: Promising Phase 2 Results for Pumitamig in Lung Cancer Trea - GuruFocus
BMY Shows Promising Results in Lung Cancer Trial - GuruFocus
Railway Pension Investments Ltd Has $63.89 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
자본화:
|
볼륨(24시간):